Stelara 90 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FCPG8
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $33,168
Award facts
- Contract value 100% obligated
- $33,168.26 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $33,168.26 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of STELARA 90 mg/ml syringes. This firm fixed-price delivery order, issued on January 8, 2026, with an ultimate completion date of January 30, 2026, carries no set-aside designation, reflecting DMS Pharmaceutical Group's competitive capability in unrestricted federal procurement. The award is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to establish multiple regional prime vendor contractors to support the Department of Defense's pharmaceutical supply needs globally.
DMS Pharmaceutical Group has demonstrated substantial federal contracting activity as a critical supplier within the military healthcare supply chain, with a proven track record supplying an extensive portfolio of pharmaceuticals including branded and generic prescription medications, biologics, vaccines, and specialty pharmaceuticals to DoD medical facilities. The PPV-G GEN V contract, awarded on November 13, 2025, with a ceiling value of $499,999,999 and completion date of December 31, 2036, authorizes the DLA to issue delivery orders for comprehensive pharmaceutical requirements supporting recurring medical supply needs across military healthcare operations worldwide. No subcontractors are identified in the award documentation.
Quick answers
Who was awarded contract SPE2DR26FCPG8?
SPE2DR26FCPG8 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 8, 2026.
How much is contract SPE2DR26FCPG8 worth?
The government has obligated $33,168 on SPE2DR26FCPG8.
Is contract SPE2DR26FCPG8 an order under another contract?
Yes. SPE2DR26FCPG8 is a delivery order under SPE2DR25D9131, an indefinite delivery contract.
Was contract SPE2DR26FCPG8 competed?
The extent of competition for SPE2DR26FCPG8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award